You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIron Dextran
Accession NumberDB00893  (APRD01053)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionIron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.
Structure
Thumb
Synonyms
Dexferrum
Dextran iron
Iron dextran complex
External Identifiers
  • UNII-95HR524N2M
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DexferrumInjection, solution50 mg/mLIntravenousAmerican Regent, Inc.1998-10-01Not applicableUs
DexferrumInjection, solution50 mg/mLIntravenousAmerican Regent, Inc.1996-03-01Not applicableUs
InfedInjection50 mg/mLIntramuscular; IntravenousActavis Pharma, Inc.1974-04-29Not applicableUs
InfedInjection, solution50 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CosmoFerB. Braun
FeosolGlaxoSmithKline
ImferonSanofi-Aventis
ProferdexNew River Pharmaceuticals Inc.
Brand mixtures
NameLabellerIngredients
BiferarxMEDA Pharmaceuticals
Iron Polysaccharides Folic Acid DHAVirtus Pharmaceuticals LLC
Prefera Ob Plus DHAAlaven Pharmaceutical LLC
PreferaobAlaven Pharmaceutical LLC
Preferaob OneAlaven Pharmaceutical LLC
Preferaob Plus DHAAlaven Pharmaceutical LLC
Purevit Dualfe PlusPure Tek Corporation
Se-tan DHASeton Pharmaceuticals
Se-tan PlusSeton Pharmaceuticals
SaltsNot Available
Categories
UNII95HR524N2M
CAS number9004-66-4
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFor treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.
Structured Indications
PharmacodynamicsIron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.
Mechanism of actionAfter iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.
TargetKindPharmacological actionActionsOrganismUniProt ID
Hemoglobin subunit betaProteinyes
activator
HumanP68871 details
Hemoglobin subunit alphaProteinyes
activator
HumanP69905 details
Ferritin heavy chainProteinyes
other
HumanP02794 details
Ferritin light chainProteinyes
other
HumanP02792 details
Related Articles
AbsorptionThe major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.
Volume of distributionNot Available
Protein binding100% (after release from dextran)
Metabolism

Dextran, a polyglucose, is either metabolized or excreted.

Route of eliminationDextran, a polyglucose, is either metabolized or excreted.
Half life5 hours (some indications that it can be as long as 10 hours)
ClearanceNot Available
ToxicityLD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AsenapineAsenapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron Dextran.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.Approved
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Iron Dextran.Approved
ChlortetracyclineChlortetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.Approved
CimetidineCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Iron Dextran.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Iron Dextran.Approved
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DimercaprolDimercaprol may increase the nephrotoxic activities of Iron Dextran.Approved
Dipotassium phosphateIron Dextran can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Iron Dextran.Approved
DoxepinDoxepin can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineDoxycycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Iron Dextran.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron Dextran.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Iron Dextran.Approved
EpinastineEpinastine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Iron Dextran.Approved
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Iron Dextran.Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.Approved
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Iron Dextran.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Iron Dextran.Withdrawn
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Iron Dextran.Investigational
LansoprazoleLansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Iron Dextran.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Iron Dextran.Approved
Lipoic AcidIron Dextran can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.Approved, Investigational
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Iron Dextran.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Iron Dextran.Approved
MetiamideMetiamide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineMinocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.Approved
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Iron Dextran.Approved
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Iron Dextran.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Iron Dextran.Approved
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Iron Dextran.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Iron Dextran.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PancrelipasePancrelipase can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PantoprazolePantoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Iron Dextran.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Iron Dextran.Approved
PenicillamineIron Dextran can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron Dextran.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Iron Dextran.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.Approved, Investigational
RabeprazoleRabeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron Dextran.Approved
RanitidineRanitidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron Dextran.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Iron Dextran.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium glycerophosphateIron Dextran can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateIron Dextran can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron Dextran.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron Dextran.Approved
TAK-390MRTAK-390MR can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Iron Dextran.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron Dextran.Experimental, Investigational
TetracyclineTetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron Dextran.Approved
TriethylenetetramineThe serum concentration of Iron Dextran can be decreased when it is combined with Triethylenetetramine.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Iron Dextran.Approved, Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

William T. Monte, Laurie Scaggs, “Process for making crystalline iron dextran.” U.S. Patent US5756715, issued 1905.

US5756715
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (45.1 KB)
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
Manufacturers
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
  • Sanofi aventis us llc
  • New river pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
Injection, solutionIntravenous50 mg/mL
InjectionIntramuscular; Intravenous50 mg/mL
Injection, solutionIntramuscular; Intravenous50 mg/mL
Tablet, film coatedOral
CapsuleOral
Capsule, gelatin coatedOral
Prices
Unit descriptionCostUnit
Iron dextran comp 100 mg/2 ml38.08USD ml
Dexferrum 100 mg/2 ml vial21.6USD ml
Dexferrum 50 mg/ml vial21.6USD ml
Dexiron 50 mg/ml15.66USD ml
Infufer 50 mg/ml15.53USD ml
Infed 100 mg/2 ml vial14.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5624668 No1995-09-292015-09-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
activator
General Function:
Oxygen transporter activity
Specific Function:
Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signaling, these properties implicate it as a regulato...
Gene Name:
HBB
Uniprot ID:
P68871
Molecular Weight:
15998.34 Da
References
  1. Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. [PubMed:9629498 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
activator
General Function:
Oxygen transporter activity
Specific Function:
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name:
HBA1
Uniprot ID:
P69905
Molecular Weight:
15257.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other
General Function:
Iron ion binding
Specific Function:
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).
Gene Name:
FTH1
Uniprot ID:
P02794
Molecular Weight:
21225.47 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other
General Function:
Iron ion binding
Specific Function:
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).
Gene Name:
FTL
Uniprot ID:
P02792
Molecular Weight:
20019.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transferrin receptor binding
Specific Function:
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.
Gene Name:
TF
Uniprot ID:
P02787
Molecular Weight:
77063.195 Da
References
  1. Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. [PubMed:10084288 ]
  2. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. [PubMed:11576368 ]
  3. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. [PubMed:17316146 ]
  4. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. [PubMed:2208657 ]
  5. Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. [PubMed:272031 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:43